In the rapidly evolving landscape of antibody-drug conjugates, where novel preclinical and clinical assets are reshaping the industry, finding the right partner is paramount for progress.

Backed by almost 15 years of experience providing the antibody-drug conjugate with valuable insights and a place to meet to share successes and challenges, we came back to Asia for the 3rd World ADC Asia 2024.

With 100+ experts having joined us in Seoul, this was your chance to showcase your technology to those actively seeking for innovative yet reliable partners to take their pipelines to the next level and explore novel and ground-breaking technologies to set them apart from other companies within the field.

If you are a platform technology firm, CDMO, equipment provider, analytical and bioanalytical CROs, companion diagnostics, liquid biopsy companies, or preclinical and clinical CROs, get in touch today. The industry would love to hear from you.

Partnering with this summit was your only opportunity to benefit from early-mover advantage, achieve a foothold before this exciting and fast-paced market becomes too crowded and accelerate your efforts, identifying sales opportunities in a complex and challenging market.